Case Report: JAK1/2 Inhibition with Baricitinib in the Treatment of STING-associated Vasculopathy with Onset in Infancy

Overview

Journal Pediatr Rheumatol Online J

Publisher Biomed Central

Specialty Pediatrics

Date 2023 Oct 26

PMID 37884945

Authors

Jianqiang Wu

Qing Zhou

Hua Zhou

Meiping Lu

Affiliations

Soon will be listed here.

Abstract

Background: Gain-of-function mutations in STING1 (also known as TMEM173) which result in constitutive activation of STING, have been reported to cause STING-associated vasculopathy with onset in infancy (SAVI). Although a wider spectrum of associated manifestations and perturbations in disease onset have been observed since its description, the genotype-phenotype correlations are not definite, and there is no established treatment protocol for SAVI.

Case Presentation: Herein, we report a kindred, heterozygous STING mutation (p.V155M) in which the 2-year-old proband suffered from severe interstitial lung disease (ILD) while her father was initially misdiagnosed with connective tissue disease associated with ILD at an adult age. Baricitinib was initiated after the diagnosis of SAVI in the proband combined with steroids, and during the 14-month follow-up, the respiratory symptoms were improved. However, as the improvement of laboratory indicators was limited, especially in autoimmune indices, and the lung CT images remained unaltered, it seems that JAK1/2 inhibition was unsatisfactory in completely controlling the inflammation of the disease in our study.

Conclusions: Baricitinib was shown to elicit some effect on the ILD but failed to control the inflammation of the disease completely. Further exploration of JAK inhibitors or other therapeutic strategies are needed to more optimally treat this inflammatory disease.

References

Li W, Wang W, Zhong L, Gou L, Wang C, Ma J . Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China. Front Immunol. 2022; 13:825367. PMC: 8995420. DOI: 10.3389/fimmu.2022.825367. View

Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V . Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2016; 76(2):468-472. DOI: 10.1136/annrheumdis-2016-209841. View

Fremond M, Hadchouel A, Berteloot L, Melki I, Bresson V, Barnabei L . Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. J Allergy Clin Immunol Pract. 2020; 9(2):803-818.e11. DOI: 10.1016/j.jaip.2020.11.007. View

Decout A, Katz J, Venkatraman S, Ablasser A . The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021; 21(9):548-569. PMC: 8029610. DOI: 10.1038/s41577-021-00524-z. View

Liu Y, Jesus A, Marrero B, Yang D, Ramsey S, Sanchez G . Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371(6):507-518. PMC: 4174543. DOI: 10.1056/NEJMoa1312625. View

Dai Y, Liu X, Zhao Z, He J, Yin Q . Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Systematic Review of Case Reports. Front Pediatr. 2021; 8:577918. PMC: 7786402. DOI: 10.3389/fped.2020.577918. View

Li J, An S, Du Z . Familial Interstitial Lung Disease Caused by Mutation of the Gene. Front Pediatr. 2020; 8:543. PMC: 7505928. DOI: 10.3389/fped.2020.00543. View

Staels F, Betrains A, Doubel P, Willemsen M, Cleemput V, Vanderschueren S . Adult-Onset ANCA-Associated Vasculitis in SAVI: Extension of the Phenotypic Spectrum, Case Report and Review of the Literature. Front Immunol. 2020; 11:575219. PMC: 7550674. DOI: 10.3389/fimmu.2020.575219. View

Skopelja-Gardner S, An J, Elkon K . Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nat Rev Nephrol. 2022; 18(9):558-572. PMC: 9214686. DOI: 10.1038/s41581-022-00589-6. View

10.

Tang X, Xu H, Zhou C, Peng Y, Liu H, Liu J . STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib. J Clin Immunol. 2019; 40(1):114-122. DOI: 10.1007/s10875-019-00690-9. View

11.

Fremond M, Crow Y . STING-Mediated Lung Inflammation and Beyond. J Clin Immunol. 2021; 41(3):501-514. DOI: 10.1007/s10875-021-00974-z. View

12.

Seo J, Kang J, Suh D, Park E, Lee C, Choi S . Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017; 139(4):1396-1399.e12. DOI: 10.1016/j.jaci.2016.10.030. View

13.

Ladoux C, Pasquet M, Crow Y, Fremond M, Roditis L . STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage. J Clin Immunol. 2023; 43(4):699-702. DOI: 10.1007/s10875-023-01431-9. View

14.

Wang Y, Wang F, Zhang X . STING-associated vasculopathy with onset in infancy: a familial case series report and literature review. Ann Transl Med. 2021; 9(2):176. PMC: 7867893. DOI: 10.21037/atm-20-6198. View

15.

Motwani M, Pawaria S, Bernier J, Moses S, Henry K, Fang T . Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models. Proc Natl Acad Sci U S A. 2019; 116(16):7941-7950. PMC: 6475399. DOI: 10.1073/pnas.1818281116. View

16.

Konno H, Chinn I, Hong D, Orange J, Lupski J, Mendoza A . Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING. Cell Rep. 2018; 23(4):1112-1123. PMC: 6092751. DOI: 10.1016/j.celrep.2018.03.115. View

17.

Nishida T, Nakano K, Inoue Y, Narumi-Kishimoto Y, Kaname T, Akashi K . Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. Intern Med. 2020; 60(7):1109-1114. PMC: 8079908. DOI: 10.2169/internalmedicine.5305-20. View

18.

Kim H, Brooks K, Tang C, Wakim P, Blake M, Brooks S . Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther. 2017; 104(2):364-373. PMC: 6089664. DOI: 10.1002/cpt.936. View

19.

Chia J, Kara Eroglu F, Ozen S, Orhan D, Montealegre-Sanchez G, de Jesus A . Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2015; 74(1):186-9. PMC: 4691417. DOI: 10.1016/j.jaad.2015.10.007. View

20.

Cetin Gedik K, Lamot L, Romano M, Demirkaya E, Piskin D, Torreggiani S . The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS. Arthritis Rheumatol. 2022; 74(5):735-751. DOI: 10.1002/art.42087. View